Financials Surgery Partners, Inc.

Equities

SGRY

US86881A1007

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
24.55 USD -1.17% Intraday chart for Surgery Partners, Inc. +3.02% -23.26%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 771.7 1,442 4,694 3,370 4,015 3,102 - -
Enterprise Value (EV) 1 3,260 3,981 7,243 5,709 6,594 5,801 5,752 6,009
P/E ratio -6.9 x -9.09 x -47.7 x -47.2 x -355 x 27.1 x 21.3 x 17.2 x
Yield - - - - - - - -
Capitalization / Revenue 0.42 x 0.78 x 2.11 x 1.33 x 1.46 x 1.03 x 0.95 x 0.87 x
EV / Revenue 1.78 x 2.14 x 3.26 x 2.25 x 2.4 x 1.93 x 1.76 x 1.68 x
EV / EBITDA 12.6 x 15.5 x 21.3 x 15 x 15.1 x 11.7 x 10.3 x 9.62 x
EV / FCF 58.3 x 42.2 x -71.4 x -83.2 x 112 x 57.5 x 24.3 x -
FCF Yield 1.71% 2.37% -1.4% -1.2% 0.89% 1.74% 4.12% -
Price to Book 2.6 x 12.7 x 3.55 x 1.28 x 2.03 x 1.54 x 1.54 x -
Nbr of stocks (in thousands) 49,296 49,719 87,889 120,948 125,498 126,371 - -
Reference price 2 15.66 29.01 53.41 27.86 31.99 24.55 24.55 24.55
Announcement Date 3/5/20 3/10/21 2/28/22 3/1/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,831 1,860 2,225 2,539 2,743 3,007 3,270 3,567
EBITDA 1 258.6 256.6 339.6 380.2 438.1 497.3 558.8 624.7
EBIT 1 171.9 148.6 223.4 247 302.3 493.9 557.9 699.7
Operating Margin 9.39% 7.99% 10.04% 9.73% 11.02% 16.42% 17.06% 19.62%
Earnings before Tax (EBT) 1 54.6 -18.8 81.2 110.3 135 295.4 349.3 -
Net income 1 -109.5 -155.6 -81.2 -54.6 -11.9 111.2 140.3 179.4
Net margin -5.98% -8.37% -3.65% -2.15% -0.43% 3.7% 4.29% 5.03%
EPS 2 -2.270 -3.190 -1.120 -0.5900 -0.0900 0.9050 1.153 1.430
Free Cash Flow 1 55.9 94.4 -101.5 -68.6 58.9 100.8 237 -
FCF margin 3.05% 5.07% -4.56% -2.7% 2.15% 3.35% 7.25% -
FCF Conversion (EBITDA) 21.62% 36.79% - - 13.44% 20.28% 42.4% -
FCF Conversion (Net income) - - - - - 90.71% 168.87% -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/5/20 3/10/21 2/28/22 3/1/23 2/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 559.2 610.2 596.2 615.4 620.6 707.1 666.2 667.6 674.1 735.4 697.4 728.8 750.8 830 768.3
EBITDA 1 76.4 114.4 77.1 86.1 96.2 120.8 90.1 100.2 105.5 142.3 94.63 114.5 126.4 161.9 108.9
EBIT 1 47.1 87.7 46 53.8 61.4 85.8 52.2 71.2 72.2 106.7 86.39 113.3 125.2 168.6 91.35
Operating Margin 8.42% 14.37% 7.72% 8.74% 9.89% 12.13% 7.84% 10.67% 10.71% 14.51% 12.39% 15.55% 16.68% 20.32% 11.89%
Earnings before Tax (EBT) 1 9.4 54.7 44.1 19.6 13.4 33.2 -0.4 49.9 32.8 52.7 38.65 67.06 76.97 123.9 50.85
Net income 1 -22.9 -0.1 12.2 -18.4 -25 -23.4 -24.9 18.9 -4.9 -1 4.822 18.75 27.89 59.72 14.83
Net margin -4.1% -0.02% 2.05% -2.99% -4.03% -3.31% -3.74% 2.83% -0.73% -0.14% 0.69% 2.57% 3.71% 7.2% 1.93%
EPS 2 -0.2800 -0.001000 0.1400 -0.2100 -0.2800 -0.2300 -0.2000 0.1500 -0.0400 -0.0100 0.0500 0.1450 0.2300 0.4200 0.1300
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/28/22 5/3/22 8/2/22 11/8/22 3/1/23 5/1/23 8/1/23 11/7/23 2/26/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,488 2,539 2,549 2,339 2,579 2,698 2,649 2,907
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 9.621 x 9.894 x 7.506 x 6.152 x 5.887 x 5.426 x 4.741 x 4.653 x
Free Cash Flow 1 55.9 94.4 -102 -68.6 58.9 101 237 -
ROE (net income / shareholders' equity) -11.7% -28.8% -0.17% 0.98% 6.36% 4.1% 6.02% 5.57%
ROA (Net income/ Total Assets) - - -0.02% 0.24% 1.87% 1.57% 2.07% -
Assets 1 - - 469,364 -22,989 -636.7 7,071 6,769 -
Book Value Per Share 2 6.020 2.290 15.00 21.70 15.80 15.90 16.00 -
Cash Flow per Share 2 2.680 5.060 1.200 1.730 2.340 3.090 3.480 -
Capex 1 73.6 42.9 57.6 80.6 88.8 115 126 -
Capex / Sales 4.02% 2.31% 2.59% 3.17% 3.24% 3.82% 3.86% -
Announcement Date 3/5/20 3/10/21 2/28/22 3/1/23 2/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
24.55 USD
Average target price
42.36 USD
Spread / Average Target
+72.56%
Consensus
  1. Stock Market
  2. Equities
  3. SGRY Stock
  4. Financials Surgery Partners, Inc.